Viewing Study NCT01805557


Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2025-12-27 @ 10:19 PM
Study NCT ID: NCT01805557
Status: COMPLETED
Last Update Posted: 2022-06-08
First Post: 2013-03-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Sponsor: Fondazione Italiana Linfomi - ETS
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Annotation Module